Inhibikase Therapeutics IKT
NASDAQ IKT
$1.93 -0.13 (-6.08%)
At close: Oct 1, 2026 · 4:00 PM EDT

Inhibikase Therapeutics (IKT) Change in Receivables (2021 - 2023)

Updated

Inhibikase Therapeutics (IKT) posted Change in Receivables of -$39,881 for FY2023, compared with $39,881 in FY2022.

Analysis

Inhibikase Therapeutics (IKT) Change in Receivables (2021 - 2023) Analysis & Trends

  • Business Quant data shows IKT's Change in Receivables at $39,881 in FY2022 (-63.8%) and $110,141 in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Receivables (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 1.35 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 1.37 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 1.09 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 333.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 140.20 Mn
10 Inhibikase Therapeutics 359.62 Mn -225.86 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 -79,602.00
Jun 30, 2023 15,083.00
Mar 31, 2023 24,638.00
Dec 31, 2022 136,180.00
Sep 30, 2022 7,290.00
Jun 30, 2022 -41,424.00
Mar 31, 2022 -62,165.00
Dec 31, 2021 -107,341.00
Sep 30, 2021 -369,099.00
Jun 30, 2021 253,807.00
Mar 31, 2021 332,774.00
API Access

Inhibikase Therapeutics Change in Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=change-in-receivables&ticker=IKT&period=max&api_key=YOUR_API_KEY